Published in Prz Gastroenterol on July 15, 2015
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33
Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology (2001) 4.28
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology (1999) 2.80
Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis (2011) 2.46
Inflammatory bowel disease. N Engl J Med (1996) 2.22
The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol (2003) 2.06
Iron, anaemia, and inflammatory bowel diseases. Gut (2004) 2.03
Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 1.62
Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis (2009) 1.13
Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol (2006) 1.12
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology (2012) 1.07
Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99
Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol (2014) 0.91
The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease. Eur J Gastroenterol Hepatol (2012) 0.90
Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf (2014) 0.86
Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.85
Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut (2007) 0.82
The impact of induction therapy with three doses of infliximab on deep histological healing in paediatric patients with active Crohn's disease. Prz Gastroenterol (2016) 0.75
Adalimumab for endoscopic and histopathological mucosal healing in paediatric patients with moderate to severe Crohn's disease. Prz Gastroenterol (2016) 0.75